Pfizer (PFE)

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

The pharma giant is taking steps to expand its portfolio.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Honeywell is spinning off its aerospace segment, which could trigger a shake-up in the Dow Jones Industrial Average this summer.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor...

The market appears to be short-sighted.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

These stocks could look like steals in a few years.

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Can Novo Nordisk thrive under intense competitive pressures?

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

Investors can find much better opportunities.